Fabre-Kramer Pharmaceuticals is a pharmaceutical company that specializes in the development of psychotropic drugs. Products in their current development pipeline include gepirone and FKB01MD for major depression, gepirone and FKW00GA for social anxiety disorder,[1] gepirone for hypoactive sexual desire disorder, FKF02SC for schizophrenia, and FKK01PD for Parkinson's disease.[2]
 | |
| Company type | S Corporation |
|---|---|
| Industry | Pharmaceuticals |
| Founded | 1992 |
| Headquarters | Houston, Texas |
Key people | Stephen Kramer (CEO) Ed Koehler (Executive Vice President, CFO) |
| Products | Travivo (Gepirone ER), FKB01MD, FKW00GA, FKF02SC, FKK01PD |
| Website | www.fabrekramer.com |
The company has also conducted clinical studies on a gepirone extended release formulation for major depression.[3][4][5]
In 2007, Fabre-Kramer Pharmaceuticals along with GlaxoSmithKline (GSK) received a 'not approvable' letter from the US Food and Drug Administration, for a gepirone extended release drug, an antidepressant treatment for adults.[6]
References
edit- ^ "Pipeline – Fabre-Kramer Pharmaceuticals, Inc". Archived from the original on March 30, 2023. Retrieved 2023-03-30.
- ^ "Product Pipeline". Fabre Kramer Pharmaceuticals. Archived from the original on 2011-11-11. Retrieved 2011-10-16.
- ^ Fabre LF, Smith LC (August 2011). "The Effect of Major Depression on Sexual Function in Women". J Sex Med. 9 (1): 231–9. doi:10.1111/j.1743-6109.2011.02445.x. PMID 21883948.
- ^ Fabre LF, Smith LC, DeRogatis LR (September 2011). "Gepirone-ER treatment of low sexual desire associated with depression in women as measured by the DeRogatis Inventory of Sexual Function (DISF) fantasy/cognition (desire) domain--a post hoc analysis". J Sex Med. 8 (9): 2569–81. doi:10.1111/j.1743-6109.2011.02330.x. PMID 21707926.
- ^ Fabre LF, Brown CS, Smith LC, Derogatis LR (May 2011). "Gepirone-ER treatment of hypoactive sexual desire disorder (HSDD) associated with depression in women". J Sex Med. 8 (5): 1411–9. doi:10.1111/j.1743-6109.2011.02216.x. PMID 21324094.
- ^ Lewcock, Anna (November 5, 2007). "GSK, Fabre-Kramer lose out on antidepressant". outsourcing-pharma.com. Archived from the original on September 10, 2023. Retrieved 2020-05-11.
External links
edit
 | This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |